Melanoma: CheckMate 204 trial

Abbreviations

No EU-CTR

Investigated (inv)
Comparator (comp)

NIVO+IPIL

na

94

na

Phase:

2

Randomisation:

Open label

Primary tumour:

Melanoma

Subtype (biomarker):

Any

Stage:

meta

Line of therapy:

L1

Primary
NIVO+IPIL
na
HR
p
intracranial CB
56%
intracranial PR
30%
na
na
na
Secondaries
NIVO+IPIL
na
HR
p
extracranial CR
7%
na
na
na
extracranial PR
43%
na
na
na
intracranial SD ≥6 mo.
2%
na
na
na
extracranial SD ≥6 mo.
6%
na
na
na
(all grades, %)
NIVO+IPIL
na
p
Fatigue
48%
NA
Increased ALT level
37%
NA
Maculopapular rash
36%
NA
Diarrhea
35%
NA
Increased AST level
34%
NA
Nausea
28%
NA
Hypothyroidism
21%
NA
Increased lipase level
15%
NA
Hyperthyroidism
13%
NA
Increased amylase level
12%
NA
  • Inclusion
  • Exclusion

- Histologically confirmed malignant melanoma with measurable metastases in the brain. Both asymptomatic and symptomatic patients. Cohort A (asymptomatic patients): At least 1 measurable brain metastasis ≥ 0.5 cm in and ≤ 3 cm in longest diameter that has not been previously irradiated. No clinical requirement for local intervention (surgery, radiosurgery, corticosteroid therapy) or other systemic therapy Cohort B (symptomatic patients): Subjects with neurologic signs and symptoms related to metastatic brain lesions are eligibile. Subjects must have at least 1 measurable brain metastasis ≥ 0.5 cm in and ≤ 3 cm in longest diameter that has not been previously irradiated. No immediate requirement (within 3 weeks prior to first treatment) for local intervention (surgery, radiosurgery, corticosteroid therapy). Steroid use is permitted as defined in the protocol. - Prior stereotactic radiotherapy (SRT) and prior excision of up to 3 melanoma brain metasta

- History of known leptomeningeal involvement (lumbar puncture not required) - Previous stereotactic or highly conformal radiotherapy within 3 weeks before the start of dosing for this study. Note the stereotactic radiotherapy field must not have included the brain index lesion(s) - Brain lesions >3 lesions which were previously treated with SRT - Brain lesion size > 3cm 3. Medical History and Concurrent Diseases a) History of whole brain irradiation b) Subjects with an active, known or suspected autoimmune disease c) Subjects with major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled d) Any concurrent malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix. For any prior invasive malignancy, at least 5 years must have elapsed since curative therapy and patients must have no residual sequelae of prior therapy e) Cohort A (asymptomatic): The use

Characteristics
NIVO+IPIL
na
Agedc-comma sex
Median age (range) yr
59 (22–81)
Male - no.(%)
65 (69)
Female - no.(%)
29 (31)
Lactate dehydrogenase - no.(%)
At or below the ULN
55 (59)
Above the ULN
39 (41)
PD-L1 expression - no.(%)
≥1%
41 (44)
<1%
34 (36)
≥5%
25 (26.6)
<5%
50 (53.2)
Stereotactic radiotherapy before study entry - no.(%)
Yes
8 (9)
No
86 (91)
No. of target lesions at pretreatment tumor - no.(%)
No lesions
1 (1)
1 lesion
49 (52)
2 lesions
23 (24)
≥3 lesions
21 (22)
BRAF status ‒ no.(%)
Mutation
54 (57.4)
No mutation
25 (26.6)
Unknown
15 (16.0)
NRAS status ‒ no.(%)
Mutation
6 (6.4)
No mutation
17 (18.1)
Unknown
71 (75.5)
Prior systemic cancer therapy ‒
Dabrafenib
8 (8.5)
Trametinib
8 (8.5)
Vemurafenib
2 (2.1)
Largest individual target lesion
<1 cm
33 (35.1)
≥1 - <2 cm
49 (52.1)
≥2 - <3 cm
10 (10.6)
≥3 cm
2 (2.1)
Ad-hoc:
no.pts inv.
no.pts comp.
NIVO+IPIL
na
HR
p
  • intracranial CB
  • intracranial PR
analisys of intracranial CB
NIVO+IPIL
na
HR (95% CI)
PD-L1 status (n)
≥1% (25)
61.0%
<1% (18)
52.9%
Largest individual target lesion (n)
<1 cm (21)
63.6%
≥1 - <2 cm (27)
55.1%
Lactate dehydrogenase (n)
≤ULN (28)
50.9%
>ULN (26)
66.7%
Lactate dehydrogenase (n)
≤2x ULN (49)
59.0%
>2x ULN (5)
45.5%
BRAF status (n)
Mutation (32)
59.3%
No mutation (11)
44.0%
Age (n)
<65 yr (38)
61.3%
≥65 yr (16)
50.0%
Sex (n)
Male (37)
56.9%
Female (17)
58.6%
analisys of intracranial PR
NIVO+IPIL
na
HR (95% CI)